This Pharma Company Stays Innovative by Doing Two Things
Harvard Business Review
MARCH 14, 2017
Roivant was addressing some sobering realities: In 2016, only 22 new drugs were approved by the U.S. Year-on-year price increases for existing therapies have allowed the industry to maintain profitability, but those short-term fixes have come at a heavy cost: decreased public satisfaction with the industry and increased political scrutiny.
Let's personalize your content